In addition, after starting the TMX treatment, the total tumor count in 3-month-old and 5-month-old TMX-treated SOS1KO/KRASG12D and SOS2KO/KRASG12D mice was dramatically reduced in comparison to their control SOS1/2WT/KRASG12D counterparts, indicating a striking dependence on SOS1/2 during the early stages of KRASG12D-driven LUAD initiation and development (Fig. 1d). Here, SOS1 is linked to neoplasm.